Robert W. Holloway, MD; Alberto A. Mendivil, MD; James E. Kendrick, MD; et al.
free access
has audio
JAMA Oncol. 2023;9(7):903-908. doi:10.1001/jamaoncol.2023.1007
This nonrandomized phase 2 clinical trial examines the clinical activity of Olvi-Vec oncolytic immunotherapy and subsequent platinum-doublet chemotherapy with or without bevacizumab in women with platinum-resistant or -refractory ovarian cancers.
-
Podcast:
Oncolytic Viral Immunochemotherapy in Patients With Ovarian Cancer
Malcolm Seth Bevel, PhD, MSPH; Meng-Han Tsai, PhD; April Parham, BS, TTS; et al.
open access
JAMA Oncol. 2023;9(7):909-916. doi:10.1001/jamaoncol.2023.0634
This cross-sectional study investigates food deserts and food swamps in US counties and their association with obesity-related cancer mortality.
Connor J. Kinslow, MD; Ann Mercurio, MS, RN; Prashanth Kumar, BA; et al.
free access
JAMA Oncol. 2023;9(7):919-927. doi:10.1001/jamaoncol.2023.0990
This cohort study evaluates the association of MGMT promoter methylation for low-grade and anaplastic gliomas with chemotherapy response.
-
Invited Commentary
MGMT Methylation Status in Grades 2 and 3 Gliomas Is Important, but Is It Prognostic?
Kelli B. Pointer, MD, PhD; Na Tosha N. Gatson, MD, PhD
JAMA Oncol
Malgorzata K. Nowakowska, BS; Rachel M. Ortega, MSA; Mackenzie R. Wehner, MD, MPhil; et al.
free access
JAMA Oncol. 2023;9(7):930-937. doi:10.1001/jamaoncol.2023.0998
This systematic review and meta-analysis examines the risk of toxic effects associated with second-generation antiandrogens administered to men with prostate cancer in randomized clinical trials.
Yana Kost, BA; Alana Deutsch, MD; Karolina Mieczkowska, MD; et al.
free access
JAMA Oncol. 2023;9(7):940-945. doi:10.1001/jamaoncol.2023.0444
This randomized clinical trial determines the efficacy of bacterial decolonization to reduce the severity of acute radiation dermatitis compared with standard of care.
Oleg Gluz, MD; Ulrike A. Nitz, MD; Matthias Christgen, MD, PhD; et al.
free access
JAMA Oncol. 2023;9(7):946-954. doi:10.1001/jamaoncol.2023.0646
This randomized clinical trial aims to determine whether neoadjuvant de-escalated chemotherapy is superior to endocrine therapy, both in combination with pertuzumab and trastuzumab, in a highly heterogeneous hormone receptor鈥損ositive/ERBB2-positive early breast cancer.
Xuan Chen, BS; Margaret A. Meyer, MS; Jennifer L. Kemppainen, MS, CGC; et al.
free access
JAMA Oncol. 2023;9(7):955-961. doi:10.1001/jamaoncol.2023.0806
This case series assesses the gene-specific risk estimates of development of pancreatic ductal adenocarcinoma (PDAC) and extra-PDAC among first-degree relatives of patients with PDAC who carry pathogenic or likely pathogenic germline variants in cancer syndrome鈥揳ssociated genes.